Table 2.

Univariate associations of obesity with sleep duration category, asthma severity y step, asthma medications, comorbidities and demographics.

	OBESITY
	OR (95% CI)	P-value
Habitual sleep duration
category:
very short (<6h)*	2.52 (1.48-4.30)	0.0007
short (≥6 and <7h)*	1.83(1.22-2.74)	0.003
long (>8 and ≤9h )*	0.91 (0.48-1.72)	0.77
very long (>9h)*	2.69 (1.38-5.26)	0.004
Asthma steps:
step 2#	1.48 (0.86-2.55)	0.16
step 3#	2.04 (1.34-3.11)	0.0009
step 4#	3.78 (2.39-5.96)	<0.0001
Using ICS	1.61 (1.08-2.40)	0.02
ICS dose:
low†	1.10 (0.67-1.81)	0.70
medium†	1.38 (0.86-2.19)	0.18
high†	2.81 (1.75-4.53)	<0.0001
Using oral corticosteroids	2.05 (1.14-3.71)	0.02
Using LABA	1.77 (1.26-2.49)	0.0009
Using LTM	1.39 (0.97-2.01)	0.08
Using theophylline	1.22 (0.37-4.09)	0.75
Rhinitis	0.43 (0.24-0.77)	0.005
Chronic sinusitis	1.26 (0.89-1.18)	0.19
Polyps	1.37 (0.88-2.14)	0.16
Psychiatric Disease	1.55 (1.08-2.24)	0.02
Age (in decades)‡	1.19 (1.07-1.33)	0.001
Gender (female vs. male)	1.20 (0.85-1.68)	0.30
African American§	6.62 (2.68-16.39)	<0.0001

^*relative to normal sleeper (7-8h);

^#relative to asthma step 1;

^†relative to no ICS use;

^‡age 18-29 was the reference category;

^§African American vs. all other races combined.

Abbreviations: OR: Odds Ratios; CI: 95% Confidence Intervals; ICS: inhaled corticosteroid; LABA: long acting β₂-agonist; LTM: leukotriene modifiers.